Lonza’s acquisition of CDMO Capsugelfrom KKR for $5.5 billion, which was initially announced in December 2016, is now complete, the company said.
In 2011, Pfizer sold Capsugel to KKR for just under $2.4 billion, and in 2013, Capsugel expanded its OINDP development and manufacturing services when it acquired Bend Research.
The announcement stated that, “With the acquisition of Capsugel, Lonza adds a trusted brand with a large breadth of technologies that it believes will expand the market reach of both companies’ contract development and manufacturing organization (CDMO) and products businesses. It also supports Lonza’s strategic ambition of getting closer to the patient and end consumer.”
Lonza CEO Richard Ridinger said, “Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance. All of these aspects will facilitate a seamless integration.”
Read the Lonza press release.
